Proto Script Pharmaceutical

Proto Script Pharmaceutical EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Proto Script Pharmaceutical (PSCR) as of Oct 10, 2026 is -33,143.00 USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -146,686.00 USD — a change of -77.41% (higher).

EBITDA

-33,143.00USD

YoY

-77.41%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Proto Script Pharmaceutical is 2016 -33,143.00 USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Proto Script Pharmaceutical was 2015 -146,686.00 USD. It decreases by -77.41% higher compared to the previous year.

The Proto Script Pharmaceutical EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2014
-232,040.00 USD
Jan 1, 2015
-146,686.00 USD
Jan 1, 2016
-33,143.00 USD
The Proto Script Pharmaceutical EBITDA history
YEAREBITDAYoY
-33,143.00USD-77.41%
-146,686.00USD-36.78%
-232,040.00USD—
Access this data via the Eulerpool API
Get Free API Key

Proto Script Pharmaceutical Stock analysis

What does Proto Script Pharmaceutical do? Proto Script Pharmaceutical Corp is an American biotechnology company specializing in the development and manufacture of innovative, high-quality drugs. The company is focused on researching new breakthrough technologies in drug manufacturing to find potential cures and treat diseases. Their business model is based on producing medications that are highly effective and of high quality while also being cost-effective and patient-friendly. They collaborate closely with biotechnology companies and academic institutions to acquire the best technologies and develop effective and innovative drugs. They have products in the areas of neurology, endocrine health, and oncology. They have also entered into partnerships with other companies to expand and further develop their products. Overall, Proto Script Pharmaceutical Corp is a groundbreaking company in the biotechnology field with decades of experience in drug development and a commitment to improving the lives of millions of people worldwide. Proto Script Pharmaceutical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Proto Script Pharmaceutical stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Proto Script Pharmaceutical is -33,143.00 USD in 2016.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Proto Script Pharmaceutical changed from -146,686.00 USD to -33,143.00 USD, representing a -77.41% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Proto Script Pharmaceutical since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Proto Script Pharmaceutical historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Income Statement — Proto Script Pharmaceutical

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Proto Script Pharmaceutical